Two Reviews Question Quality Of Cardiac PMA Trials
This article was originally published in The Gray Sheet
Executive Summary
Two recent studies question the consistency and quality of clinical trials intended to support FDA premarket approvals of cardiac devices. As one of the studies was conducted by agency scientists, new requirements for PMA studies may soon be in the offing
You may also be interested in...
FDA Articulates Design Principles For Pivotal Trials In Final Guidance
The agency prefers device pivotal trials to be randomized, double-blinded and controlled, but understands that this is “neither feasible nor practical” for some devices, according to a Nov. 7 final guidance.
FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs
Clinical studies in support of pre-market approval applications should ideally be randomized and blinded, FDA maintains in recent guidance.
FDA Guidance Emphasizes Randomized, Blinded Trials For PMAs
Clinical studies in support of pre-market approval applications should ideally be randomized and blinded, FDA maintains in recent guidance.